MIRA INFORM REPORT
|
Report Date : |
04.11.2011 |
IDENTIFICATION DETAILS
|
Name : |
QINTAR PHARMACEUTICALS |
|
|
|
|
Registered Office : |
14-A, Punjab Small Industrial Estate, Lahore Road, Sarghoda |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishment : |
2001 |
|
|
|
|
Legal Form : |
Partnership Concern |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment
Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Pakistan |
b2 |
b2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Business Name
QINTAR PHARMACEUTICALS
Full Address
|
Registered Address
& Factory |
|
14-A, |
|
Tel # |
92
(48) 3216343, 3206858 |
|
Fax # |
92
(48) 3206858 |
Short Description Of Business
|
a. |
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
b. |
Year Established |
2001 |
|
c. |
National Tax # |
1768889 |
Branches
In Lahore
Legal Status
|
Subject Concern was established as a Partnership business in 2001 |
Details of Managing Partner /
Partners
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Sarfraz Ahmad Mr. Muhammad Riaz Masud Mr. Muhammad Azhar Mehmood |
Pakistani Pakistani Pakistani |
14-A, 14-A, 14-A, |
Business Business Business |
Managing Partner Partner Partner |
Associates
A. Subsidiary
None
B. Associated
Companies
- Do -
Products
(1) Subject Concern is engaged in manufacture & marketing of Pharmaceutical Products.
(2) It purchases raw material against L/C, D/A, D/P basis
(3) It sells against Cash / Credit Terms to its local customers.
(4) Its’ major customers are Distributors, Traders, Pharmacies & Hospitals located at Punjab.
(5) Subject operates from caption leased factory premises of area measuring 3,000 Sq.Yard. which is situated at industrial area of Sarghoda.
(6) Subject employs about 50 persons in its set up.
Products
|
ARMEX, CITALOCIT, FANSIQIN, FERTOZ,
FLUREST, GASTIZOL, GL-RON, GYNOX-V, HEPAMYRIN, MEFNAX, MESPAREX, MEX,
MYLIFAM, NIPGESIC, NOTENSE, QINEX, SERZINE, SINGOKAST, WORCYT |
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2009 |
40,000,000/-
(Estimated) |
Capacity & Production
The capacity and production of the concern’s plant is indeterminable as it is multi- product and involves various processes of manufacture.
Distributors Network
Mainly exist at major cities of Punjab Province
Bankers
·
The Bank of
· Habib Bank Limited, Pakistan.
· Askari Bank Limited, Pakistan.
· United Bank Limited, Pakistan.
· MCB Bank Limited, Pakistan.
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 86.30 |
|
UK Pound |
1 |
Rs. 137.60 |
|
Euro |
1 |
Rs. 118.50 |
Memberships
· Sarghoda Chamber of Commerce & Industry.(SCCI)
Comments
Subject Concern was established in 2001 and is engaged in
manufacture & marketing of Pharmaceutical Products.
Trade relations are reported as fair. Subject can be considered for
normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.37 |
|
UK Pound |
1 |
Rs.78.50 |
|
Euro |
1 |
Rs.67.59 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.